Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Cysteine engineered fibronectin type iii domain binding molecules

A technology of cysteine ​​and fibronectin, applied in the direction of peptide/protein components, animal/human proteins, anti-animal/human immunoglobulins, etc.

Inactive Publication Date: 2019-04-26
JANSSEN BIOTECH INC
View PDF22 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, modification in cysteine ​​thiol groups obtained by mutation of various amino acid residues of the protein to cysteine ​​amino acids can be problematic, especially at unpaired (free Cys) residues or relative In the case of those residues susceptible to reaction or oxidation

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Cysteine engineered fibronectin type iii domain binding molecules
  • Cysteine engineered fibronectin type iii domain binding molecules
  • Cysteine engineered fibronectin type iii domain binding molecules

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0365] Example 1: Construction of Tencon Library

[0366] Tencon (SEQ ID NO:1) is an immunoglobulin-like scaffold type III fibronectin (FN3) domain designed from the consensus sequence of fifteen FN3 domains of human tenascin-C (Jacobs et al., Protein Engineering, Design, and Selection, 25:107-117, 2012; US Patent Publication 2010 / 0216708). The crystal structure of Tencon shows six surface exposed loops connecting seven β-strands. The selected residues within these loops or each loop can be randomized to construct a type III fibronectin (FN3) domain library that can be used to select novel molecules that bind to specific targets.

[0367] Tencon:

[0368] Lpapknlvvsevtedslrlswtapdaafdsfliqyqesekvgeainltvpgsersydltglkpgteytvsiygvkgghrsnplsaeftt (SEQ ID NO 1):

[0369] TCL1 library construction

[0370] The library TCL1 designed to randomize only the FG loop of Tencon (SEQ ID NO:1) was constructed for use with the cis-display system (Jacobs et al., Protein Engineering, Design, and Sele...

Embodiment 2

[0388] Example 2: Selection of type III fibronectin (FN3) domain that binds EGFR and inhibits EGF binding

[0389] Library screening

[0390] The cis display was used to select EGFR binding domains from TCL1 and TCL2 libraries. The recombinant human extracellular domain of EGFR fused to IgG1 Fc (R&D Systems) was biotinylated using standard methods and used for panning (residues 25-645 of the full-length EGFR of SEQ ID NO: 73). For in vitro transcription and translation (ITT), 2-6 µg of library DNA are incubated with 0.1 mM intact amino acids, 1X S30 premix fraction and 30 µL S30 extract (Promega) in a total volume of 100 µL and incubated at 30°C . After 1 hour, 450 μL of blocking solution (PBS pH 7.4, supplemented with 2% bovine serum albumin, 100 μg / mL herring sperm DNA, and 1 mg / mL heparin) was added, and the reaction was incubated on ice for 15 minutes. EGFR-Fc was assembled by mixing recombinant human EGF (R&D Systems) and biotinylated recombinant EGFR-Fc in blocking solutio...

Embodiment 3

[0408] Example 3: Characterization of EGFR-binding FN3 domain that inhibits EGF binding

[0409] Large-scale expression, purification and endotoxin removal

[0410] The 9 FN3 domains shown in Table 4 are enlarged to provide more materials for detailed characterization. Using an overnight culture containing each EGFR-binding FN3 domain variant, the overnight culture was diluted 1 / 80 in 0.8 L Terrific broth supplemented with 100 µg / mL ampicillin and inoculated into fresh medium, Incubate with shaking at 37°C. When the optical density at 600 nm reached about 1.2-1.5 by adding IPTG to a final concentration of 1 mM, the culture was induced and the temperature was lowered to 30°C. After 4 hours, the cells were collected by centrifugation, and the cell pellets were stored at -80°C until needed.

[0411] For cell lysis, the thawed pellets were thawed at 5mL BugBuster per gram of pellets ® Resuspended in supplement with 25U / mL Benzonase ® (Sigma-Aldrich) and 1kU / mL rLysozyme ™ (Novagen...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
affinityaaaaaaaaaa
sizeaaaaaaaaaa
Login to View More

Abstract

Cysteine engineered monospecific and bispecific EGFR and / or c-Met FN3 domain containing molecules comprising one or more free cysteine amino acids are prepared by mutagenizing a nucleic acid sequenceof a parent molecule and replacing one or more amino acid residues by cysteine to encode the cysteine engineered FN3 domain containing monospecific or bispecific molecules; expressing the cysteine engineered FN3 domain containing molecules; and recovering the cysteine engineered FN3 domain containing molecule, isolated cysteine engineered monospecific or bispecific FN3 domain containing moleculesmay be covalently attached to a detection label or a drug moiety and used therapeutically.

Description

Technical field [0001] The present invention relates to binding molecules engineered with cysteine ​​residues, and methods of making them and using them. More specifically, the present invention relates to type III fibronectin (FN3) domain molecules, which can bind to cysteine-engineered EGFR and / or c-Met. Background technique [0002] Epidermal growth factor receptor (EGFR or ErbBl or HER1) is a 170kDa transmembrane glycoprotein, which is encoded by the c-erbBl proto-oncogene. EGFR is a member of the human epidermal growth factor receptor (HER) family of receptor tyrosine kinases (RTK), which includes HER2 (ErbB2), HER3 (ErbB3) and HER4 (ErbB4). These RTKs share a homologous structure consisting of a ligand-binding extracellular domain (ECD), a single transmembrane domain, and an intracellular domain, which includes a catalytic kinase domain and a C-terminal tail. EGFR signal transduction is triggered by ligand binding and then induces conformational changes, dimerization and...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/00A61K38/39C07K14/78C07K16/28C12N15/09
CPCC07K14/78C07K14/71C07K14/82C07K2319/31C07K2319/30C12N15/64C12N15/09C12N15/63C07K2319/74C07K2319/00C07K19/00A61K38/39A61K31/25C07K2318/20C07D207/448
Inventor M.安德森R.阿塔M.迪姆S.戈德伯格L.玄S.雅各布斯A.金D.克莱因S.摩尔斯K.奥奈尔K.皮查
Owner JANSSEN BIOTECH INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com